The efficacy and safety of LAAC for stroke prevention in patients with HCM and AF who cannot tolerate anticoagulation remain debated TAKE-HOME MESSAGE: Although LAAC is not a standard stroke prevention therapy for HCM patients with AF, it represents a viable alternative in high-bleeding-risk scenarios and requires meticulous planning, vigilant DRT surveillance, and individualized antithrombotic management.
Lu et al. (2026) studied this question.